Schizophrenia research has been transformed by the 2024 FDA approval of xanomeline-trospium (Cobenfy), the first non-dopaminergic antipsychotic in decades. The approval validated muscarinic targeting as an antipsychotic mechanism and opened new research directions beyond the dopamine D2 antagonism that defined antipsychotics for 70 years. For patients with schizophrenia, clinical trials for schizophrenia may offer access to next-generation muscarinic agents, other novel mechanisms, and approaches for treatment-resistant disease. This guide covers how to find schizophrenia trials, active research areas, eligibility considerations, and resources.
Categories of schizophrenia trials
Active schizophrenia trials in 2026 include:
Muscarinic antipsychotics: Following xanomeline-trospium approval, multiple muscarinic agents are in development including more selective M1/M4 agonists with potentially better tolerability.
TAAR1 agonists: Trace amine-associated receptor 1 agonists like ulotaront target a non-dopaminergic mechanism. Phase 3 trials ongoing.
Cognitive impairment in schizophrenia: Cognitive symptoms are often the most disabling and least responsive to current treatments. Trials specifically target cognitive impairment.
Negative symptom treatments: Negative symptoms (avolition, anhedonia, social withdrawal) are also poorly addressed by current treatments. Targeted trials.
Treatment-resistant schizophrenia: Beyond clozapine, novel approaches for patients who don’t respond to standard antipsychotics.
Long-acting injectables: New formulations and intervals for adherence support.
Where to find schizophrenia trials
Resources:
- ClinicalTrials.gov
- NAMI
- Schizophrenia & Psychosis Action Alliance
- Major academic psychiatry programs
- NIMH research initiatives
Typical eligibility for schizophrenia trials
Common inclusion criteria:
- Schizophrenia or schizoaffective disorder diagnosis meeting DSM-5 criteria
- Specific symptom severity (PANSS or other scales)
- Stable enough to participate (acute exacerbation may exclude)
- Adequate medical status
Common exclusion criteria:
- Acute exacerbation requiring hospitalization (varies by trial)
- Active substance use disorder
- Significant medical conditions
- Pregnancy
Frequently Asked Questions
What is xanomeline-trospium?
Cobenfy, the first non-dopaminergic antipsychotic, FDA-approved in 2024. Targets muscarinic receptors. Trials of next-generation muscarinic agents continue.
Can I participate if I’m on clozapine?
Some trials specifically target patients on clozapine for additional therapy; others exclude due to drug interactions. Trial-specific.
Are trials for cognitive impairment in schizophrenia available?
Yes. Cognitive symptoms remain poorly addressed by current treatments. Specific trials test cognitive enhancement approaches.
What about negative symptoms?
Active research area. Multiple mechanisms being tested specifically for negative symptoms.
How long do schizophrenia trials typically last?
Acute treatment trials are 4-12 weeks; maintenance trials run 6-24 months.
The bottom line on schizophrenia trials
Schizophrenia research has expanded with muscarinic antipsychotics, TAAR1 agonists, and approaches targeting cognitive and negative symptoms. The xanomeline-trospium approval opened new research directions. Major academic psychiatry programs and patient advocacy organizations provide trial resources.